Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
DGX Stock News and Mentions of Quest Diagnostics Inc. Stocktwits
Updated: April 28, 2024 (09:14)
Sector: Financial
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Quest Diagnostics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Quest Diagnostics Inc. (DGX).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Quest Diagnostics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Quest Diagnostics Inc. (DGX)
April 25, 2024 (06:52) / "Stocknews.com" (by Defense World Staff)
Quest Diagnostics ( NYSE:DGX ) Upgraded to Buy at StockNews.com
Quest Diagnostics ( NYSE:DGX - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a report released on Thursday. A number of other analysts also recently weighed in on the stock.
In Article Trend: Somewhat-Bullish
April 24, 2024 (19:45) / "Benzinga" (by Benzinga Insights)
Peering Into Quest Diagnostics's Recent Short Interest - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics's DGX short percent of float has fallen 16.83% since its last report. The company recently reported that it has 2.55 million shares sold short, which is 2.62% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
April 23, 2024 (16:44) / "Benzinga" (by Vandana Singh)
Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic Why Is Quest Diagnostics Stock Surging Today? - Quest Diagnostics ( NYSE:DGX )
Tuesday, Quest Diagnostics Inc DGX posted first-quarter adjusted EPS of $2.04, beating the consensus of $1.86. Sales came in at $2.37 billion, up 1.5% Y/Y, higher than the Wall Street estimate of $2.29 billion.
In Article Trend: Somewhat-Bullish
April 23, 2024 (13:54) / "Zacks Commentary" (by Zacks Equity Research)
Quest Diagnostics ( DGX ) Q1 Earnings Top Estimates, Margins Down
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
In Article Trend: Somewhat-Bullish
April 23, 2024 (11:55) / "Zacks Commentary" (by Zacks Equity Research)
Quest Diagnostics ( DGX ) Beats Q1 Earnings and Revenue Estimates
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 9.68% and 3.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Somewhat-Bullish
April 22, 2024 (13:16) / "Zacks Commentary" (by Zacks Equity Research)
Unlocking Q1 Potential of Quest Diagnostics ( DGX ) : Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Quest Diagnostics (DGX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
In Article Trend: Neutral
April 22, 2024 (10:44) / "Benzinga" (by Shanthi Rexaline)
S&P 500, Nasdaq To Open In The Green Today: What's Pushing Stock Futures Higher? - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
Wall Street appears to be shrugging off rate worries as major stock index futures were moderately higher in early pre-market trading on Monday in the hopes of getting some respite from Big Tech earnings.
In Article Trend: Neutral
April 21, 2024 (21:45) / "Benzinga" (by Shanthi Rexaline)
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
As the market runs into rough weather, the importance of the upcoming week's earnings cannot be emphasized enough. A lot is riding on the earnings reports of companies like Tesla, Inc. TSLA, Meta Platforms, Inc. META, Microsoft Corp. MSFT and Alphabet, Inc. GOOGL ( GOOG ) .
In Article Trend: Neutral
April 19, 2024 (15:33) / "Benzinga" (by Globe Newswire)
CIO Leadership: HMG Strategy Will Recognize Six World-Class CIOs & Business Tech Leaders at its 16th Annual New Jersey C-Level Technology Leadership Summit on May 23
WESTPORT, Conn., April 19, 2024 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 platform for enabling technology executives to reimagine the enterprise and reshape the business world, is thrilled to announce that it will be recognizing six top-tier business technology leaders for their ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 17, 2024 (06:14) / "Stocknews.com" (by Defense World Staff)
Quest Diagnostics ( NYSE:DGX ) Lowered to Hold at StockNews.com
Quest Diagnostics ( NYSE:DGX - Get Free Report ) was downgraded by equities research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Wednesday.
In Article Trend: Somewhat-Bullish
April 16, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Earnings Preview: Quest Diagnostics ( DGX ) Q1 Earnings Expected to Decline
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 15, 2024 (13:47) / "Zacks Commentary" (by Zacks Equity Research)
Quest Diagnostics ( DGX ) to Post Q1 Earnings: What's in Store?
Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:30) / "PR Newswire" (by Inc.)
EarlyDiagnostics, Inc. Co-CEO Gregory C. Critchfield, M.D. M.S., Receives Utah Governor's Medal for Science and Technology
EarlyDiagnostics, Inc. Co-CEO Gregory C. Critchfield, M.D. M.S., Receives Utah Governor's Medal for Science and ... PR ...
In Article Trend: Somewhat-Bullish
April 11, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Myriad Genetics ( MYGN ) Announces Favorable Research Results
Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.
In Article Trend: Somewhat-Bullish
April 10, 2024 (07:24) / "Stocknews.com" (by Defense World Staff)
Quest Diagnostics ( NYSE:DGX ) Rating Increased to Buy at StockNews.com
StockNews.com upgraded shares of Quest Diagnostics ( NYSE:DGX - Free Report ) from a hold rating to a buy rating in a research note published on Tuesday. A number of other equities research analysts also recently issued reports on the company.
In Article Trend: Somewhat-Bullish
April 9, 2024 (13:03) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp's ( LH ) Strategic Alliances Aid Amid Macroeconomic Woes
Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
In Article Trend: Somewhat-Bullish
April 9, 2024 (12:01) / "GlobeNewswire" (by Mainz BioMed NV)
Mainz Biomed Reports Full Year 2023 Financial Results
BERKELEY, Calif. and MAINZ, Germany, April 09, 2024 ( GLOBE NEWSWIRE ) -- Mainz Biomed N.V. ( NASDAQ:MYNZ ) ( "Mainz Biomed" or the "Company" ) , a leader in molecular genetics diagnostic solutions for early cancer detection, announced today financial results for the fiscal year ended December ...
In Article Trend: Neutral
April 8, 2024 (17:26) / "Forbes" (by Chase Feiger)
How This CEO Consumerized Cancer Diagnostics Into A $13B Enterprise
Exact Sciences' ( NDAQ: EXAS ) history is a tale of two halves. Founded in 1995 in Marlborough, Massachusetts, "Exact," as the company is known, went public in 2001 but struggled to find its footing, flirting with delisting.
In Article Trend: Somewhat-Bullish
April 4, 2024 (09:07) / "GlobeNewswire" (by BioPorto A/S)
Notice convening the Annual General Meeting in BioPorto A/S
April 4, 2024Announcement no. ...
In Article Trend: Neutral
April 3, 2024 (15:22) / "Zacks Commentary" (by Zacks Equity Research)
Quest Diagnostics ( DGX ) Collaborates With Broad Clinical Labs
Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
In Article Trend: Neutral
April 2, 2024 (14:45) / "Benzinga" (by Globe Newswire)
Anatomic Pathology Market Size is projected to reach USD 45.27 billion by 2031, growing at a CAGR of 9.88%: Straits Research
New York, United States, April 02, 2024 ( GLOBE NEWSWIRE ) -- Anatomic pathology is a broad field that includes subdomains such as cytopathology, gastrointestinal pathology, gynecological pathology, musculoskeletal pathology, renal pathology, dermatopathology and immunohistochemistry, in-situ ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (10:15) / "PR Newswire" (by Research and Markets)
World Molecular Diagnostics for Cancer Markets, 2023-2024 and 2027 with Profiles of Over 120 Companies
DUBLIN, March 28, 2024 /PRNewswire/ -- The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.
In Article Trend: Neutral
March 25, 2024 (11:03) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp ( LH ) Boost Diagnostics Suite With New Biomarker Test
Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.
In Article Trend: Somewhat-Bullish
March 21, 2024 (14:50) / "Benzinga" (by Globe Newswire)
Global Revenue Cycle Management ( RCM ) Market Size is projected to reach USD 586.5 billion by 2031, growing at a CAGR of 12.4%: Straits Research
New York, United States, March 21, 2024 ( GLOBE NEWSWIRE ) -- Revenue cycle management ( RCM ) is the process utilized by healthcare systems worldwide to monitor the revenue from patients, from their initial appointment or encounter to the payment of their final balance.
In Article Trend: Somewhat-Bullish
March 15, 2024 (23:45) / "PR Newswire" (by Research and Markets)
Clinical Laboratory Services Market Size, Share & Trends Analysis Report 2024: A USD 286.77 Billion Market by 2030, Registering a CAGR of 3.5% from 2024 to 2030
Clinical Laboratory Services Market Size, Share & Trends Analysis Report 2024: A USD 286.77 Billion Market by 2030 ... PR ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:25) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp ( LH ) Expands Strategic Alliances, Test Sales Fall
Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.
In Article Trend: Somewhat-Bullish
March 14, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
DaVita HealthCare ( DVA ) Up 12% Since Last Earnings Report: Can It Continue?
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Somewhat-Bullish
March 13, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Global In Vitro Toxicology Testing Market Size is projected to reach USD 28.19 billion by 2031, growing at a CAGR of 10.8%: Straits Research
New York, United States, March 13, 2024 ( GLOBE NEWSWIRE ) -- In Vitro toxicology testing is used to determine the toxicity of a substance on non-living cells or tissues. It is a crucial component of preclinical safety evaluation in the pharmaceutical, chemical, and regulatory industries.
In Article Trend: Somewhat-Bullish
March 8, 2024 (16:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Encompass Health ( EHC ) Up 5.3% Since Last Earnings Report?
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Encompass Health ( EHC ) Up 5.3% Since Last Earnings Report?
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Somewhat-Bullish
March 7, 2024 (07:31) / "Benzinga" (by Globe Newswire)
Biomarkers Market to Reach USD 125.6 billion by 2031, Projected a CAGR of 10.4%: Report Analysis by Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 07, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global biomarkers market is estimated to flourish at a CAGR of 10.4% from 2023 to 2031.
In Article Trend: Somewhat-Bullish
March 5, 2024 (13:15) / "Benzinga" (by Benzinga Insights)
( DGX ) - Analyzing Quest Diagnostics's Short Interest - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics's DGX short percent of float has fallen 13.05% since its last report. The company recently reported that it has 2.97 million shares sold short, which is 3.53% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
March 5, 2024 (13:01) / "GlobeNewswire" (by Mainz BioMed NV)
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
• Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration • Mainz Biomed's Pivotal FDA PMA clinical trial ( ReconAAsense ) evaluating gold standard self-administered colorectal cancer ...
In Article Trend: Neutral
March 1, 2024 (14:36) / "Zacks Commentary" (by Zacks Equity Research)
Quest Diagnostics ( DGX ) Hurt by Lower Testing Sales, Competition
Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.
In Article Trend: Somewhat-Bullish
Related stocks from Financial sector
This website uses cookies to ensure you get the best experience on our website